The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.

Published

Journal Article

Forty-five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5-fluorouracil, and methotrexate with folinic acid rescue. This regimen was designed to produce rapid and extensive tumor shrinkage prior to high-dose alkylating agent chemotherapy with autologous marrow support. The overall response rate was 91%, and 38% of patients achieved complete clinical responses after a mean of 70 days on treatment. Hematologic and mucosal toxicity were extensive, but no toxic deaths were noted. AFM is a potent remission induction regimen for metastatic breast cancer, but its considerable toxicity suggests caution in its use for routine breast cancer treatment.

Full Text

Duke Authors

Cited Authors

  • Jones, RB; Shpall, EJ; Shogan, J; Affronti, ML; Coniglio, D; Hart, L; Halperin, E; Iglehart, JD; Moore, J; Gockerman, J

Published Date

  • August 1990

Published In

Volume / Issue

  • 66 / 3

Start / End Page

  • 431 - 436

PubMed ID

  • 2364358

Pubmed Central ID

  • 2364358

Electronic International Standard Serial Number (EISSN)

  • 1097-0142

International Standard Serial Number (ISSN)

  • 0008-543X

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19900801)66:3<431::aid-cncr2820660305>3.0.co;2-x

Language

  • eng